University of Texas System

Other

Michael A Curran

Bianka Prinz

Dongxing Zha

Carlo Toniatti

Ashvin R Jaiswal

Kui Shin Voo

Nadthakarn Boland

Philip Jones

Maria Emilia Di Francesco

Eric Krauland

David D Caulfield

Robert Tarini

Nga Rewa Houston

Kui Voo

The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Human PD-L2 antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Human PD-L1 antibodies and methods of use therefor

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

Airports and other public places require security measures for the screening of human subjects for illicit objects and materials concealed from view beneath clothing. However, at present most of such screening processes involve only metal detectors, which are inherently incapable of detecting non-metallic illicit objects and materials. For this reason, there remains a strong need for novel systems and methods that can detect all types of materials. The present invention provides for a portal detection system that is configured for safe, rapid, and non-invasive scanning of human subjects. For this purpose, the portal detection system utilizes acoustic technology to achieve this end. The portal detection systems of the present invention may optionally be used in conjunction with conventional metal detection means. The invention encompasses portal detection systems, their use in scanning human subjects, and corresponding methods of scanning human subjects for illicit objects and substances.

Growing community of inventors

Pearland, TX, United States of America

Michael A Curran